Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (6)

2021

  1. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

2016

  1. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

    Annals of Oncology, Vol. 27, pp. vi213

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2005

  1. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667

  2. Genetic abnormalities and patterns of antigenic expression in multiple myeloma

    Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667